FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Vukovic Vojo (Last) (First) (Middle) C/O SYNTA PHARMACEUTICALS CORP. 45 HARTWELL AVENUE (Street) LEXINGTON MA 02421					SYN SNTA 3. Dat 09/13	2. Issuer Name and Ticker or Trading Symbol SYNTA PHARMACEUTICALS CORP [SNTA] 3. Date of Earliest Transaction (Month/Day/Year) 09/13/2012 4. If Amendment, Date of Original Filed (Month/Day/Year)								Relationship of Reporting Person(s) to Issuer neck all applicable) Director 10% Owner X Officer (give title Other (specify below) below) SVP, Chief Medical Officer Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate) (Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date,					4. Securities Acquired Disposed Of (D) (Instr. and 5) Amount (A) or (D)		Instr. 3, 4	Securi Benefi Owned Follov Repor Transa	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transact Code (In 8)		on of		6. Date Exercisable a Expiration Date (Month/Day/Year)			d 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Number of Shares					
Employee Stock Option (Right to Buy)	\$8.05	09/13/2012			A		25,000		(1)	09/	/13/2022	Common Stock	25,000	\$0	25,000		D	

Explanation of Responses:

 $1. \ The \ option \ vests \ as \ to \ 25\% \ of \ the \ shares \ on \ September \ 13, \ 2013 \ and \ as \ to \ an \ additional \ 6.25\% \ of \ the \ shares \ on \ the \ last \ day \ of \ each \ successive \ three-month \ period \ thereafter.$

/s/ Ann Margaret Eagleston, Attorney-in-Fact 09/17/2012

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.